Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s40336-014-0098-3.

Title:
Amyloid PET imaging: applications beyond Alzheimer’s disease | Clinical and Translational Imaging
Description:
As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers a unique opportunity to detect the presence of this protein in the human body during life. Besides Alzheimer’s disease (AD), deposits of beta-amyloid in the brain are also present in other neurodegenerative diseases associated to dementia, such as Parkinson’s disease and dementia with Lewy bodies, as well as in other processes affecting brain function, such as cerebral amyloid angiopathy, brain trauma, Down’s syndrome and meningiomas, as shown by post-mortem pathology studies. Furthermore, in systemic amyloidosis other organs besides the brain are affected, and amyloid PET imaging may be suitable for the identification of these extra-cerebral amyloid depositions. Finally, the potential use of amyloid PET tracer accumulation in cerebral white matter (WM) as a marker of myelin is being investigated, leading to some promising results in patients with WM lesions and multiple sclerosis. In this article, a review of the ongoing research pointing to a broader application of amyloid PET imaging in clinical practice beyond AD is provided.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

amyloid, pet, imaging, article, pubmed, google, scholar, cpib, patients, betaamyloid, brain, disease, dementia, cas, clinical, dlb, uptake, deposition, reported, studies, cerebral, neurol, alzheimers, caa, med, tbi, binding, central, lewy, amyloidosis, found, patient, pathology, lesions, study, potential, tracer, subjects, table, results, diagnosis, nucl, higher, body, angiopathy, pdd, positive, age, diseases, syndrome,

Topics {✒️}

article download pdf full size image perivascular beta-amyloid depositions 18f-fdg pet scans 18f-labeled amyloid tracers extra-cerebral amyloid depositions registered 11c-pib slices positron emission tomography pro-caa position statement blood–brain barrier disruption show beta-amyloid plaques cortical beta-amyloid deposition 11c-pib retention index striatal 11c-pib retention 11c-pib positive scans global 11c-pib retention positive 18f-florbetapir uptake amyloid-ss-directed immunotherapy lower 11c-pib retention c-pib pet imaging magnetic resonance imaging 11c-pib pet imaging peptide-related cerebral amyloidosis anti-beta-amyloid immunotherapy regional beta-amyloid depositions brain beta-amyloid depositions cerebral beta-amyloid deposition 18f-flutemetamol pet/ct parenchymal beta-amyloid plaques differential 11c-pib retention 3h-pib autoradiography performed regional 11c-pib binding negative 11c-pib scan 11c-pib uptake patterns reduced 11c-pib uptake substantial beta-amyloid deposition jack cr jr brain beta-amyloid deposition global 11c-pib binding global 11c-pib ratio efficacious disease-modifying drugs 11c-pib uptake compared brain β-amyloid deposition diffuse beta-amyloid deposition beta-amyloid deposition patterns progressive beta-amyloid accumulation higher 11c-pib uptake cortical gray matter cerebral white matter [18f]florbetaben pet study

Questions {❓}

  • Aarsland D, Ballard CG, Halliday G (2004) Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity?
  • Chen W, Dilsizian V (2012) Molecular imaging of amyloidosis: will the heart be the next target after the brain?
  • Jellinger KA, Attems J (2006) Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?
  • Lhommel R, Sempoux C, Ivanoiu A, Michaux L, Gerber B (2014) Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Amyloid PET imaging: applications beyond Alzheimer’s disease
         description:As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers a unique opportunity to detect the presence of this protein in the human body during life. Besides Alzheimer’s disease (AD), deposits of beta-amyloid in the brain are also present in other neurodegenerative diseases associated to dementia, such as Parkinson’s disease and dementia with Lewy bodies, as well as in other processes affecting brain function, such as cerebral amyloid angiopathy, brain trauma, Down’s syndrome and meningiomas, as shown by post-mortem pathology studies. Furthermore, in systemic amyloidosis other organs besides the brain are affected, and amyloid PET imaging may be suitable for the identification of these extra-cerebral amyloid depositions. Finally, the potential use of amyloid PET tracer accumulation in cerebral white matter (WM) as a marker of myelin is being investigated, leading to some promising results in patients with WM lesions and multiple sclerosis. In this article, a review of the ongoing research pointing to a broader application of amyloid PET imaging in clinical practice beyond AD is provided.
         datePublished:2015-01-21T00:00:00Z
         dateModified:2015-01-21T00:00:00Z
         pageStart:39
         pageEnd:55
         license:https://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s40336-014-0098-3
         keywords:
            Amyloid PET
            Brain trauma
            Cardiac amyloidosis
            Multiple sclerosis
            Cerebral amyloid angiopathy
            Down’s syndrome
            Nuclear Medicine
            Imaging / Radiology
            Diagnostic Radiology
            Medical and Radiation Physics
            Interventional Radiology
            Radiotherapy
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig6_HTML.jpg
         isPartOf:
            name:Clinical and Translational Imaging
            issn:
               2281-7565
               2281-5872
            volumeNumber:3
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Milan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ana M. Catafau
               affiliation:
                     name:Piramal Imaging GmbH
                     address:
                        name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Santiago Bullich
               affiliation:
                     name:Piramal Imaging GmbH
                     address:
                        name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Amyloid PET imaging: applications beyond Alzheimer’s disease
      description:As a biomarker of beta-amyloid, positron emission tomography (PET) amyloid imaging offers a unique opportunity to detect the presence of this protein in the human body during life. Besides Alzheimer’s disease (AD), deposits of beta-amyloid in the brain are also present in other neurodegenerative diseases associated to dementia, such as Parkinson’s disease and dementia with Lewy bodies, as well as in other processes affecting brain function, such as cerebral amyloid angiopathy, brain trauma, Down’s syndrome and meningiomas, as shown by post-mortem pathology studies. Furthermore, in systemic amyloidosis other organs besides the brain are affected, and amyloid PET imaging may be suitable for the identification of these extra-cerebral amyloid depositions. Finally, the potential use of amyloid PET tracer accumulation in cerebral white matter (WM) as a marker of myelin is being investigated, leading to some promising results in patients with WM lesions and multiple sclerosis. In this article, a review of the ongoing research pointing to a broader application of amyloid PET imaging in clinical practice beyond AD is provided.
      datePublished:2015-01-21T00:00:00Z
      dateModified:2015-01-21T00:00:00Z
      pageStart:39
      pageEnd:55
      license:https://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s40336-014-0098-3
      keywords:
         Amyloid PET
         Brain trauma
         Cardiac amyloidosis
         Multiple sclerosis
         Cerebral amyloid angiopathy
         Down’s syndrome
         Nuclear Medicine
         Imaging / Radiology
         Diagnostic Radiology
         Medical and Radiation Physics
         Interventional Radiology
         Radiotherapy
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40336-014-0098-3/MediaObjects/40336_2014_98_Fig6_HTML.jpg
      isPartOf:
         name:Clinical and Translational Imaging
         issn:
            2281-7565
            2281-5872
         volumeNumber:3
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Milan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ana M. Catafau
            affiliation:
                  name:Piramal Imaging GmbH
                  address:
                     name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Santiago Bullich
            affiliation:
                  name:Piramal Imaging GmbH
                  address:
                     name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Clinical and Translational Imaging
      issn:
         2281-7565
         2281-5872
      volumeNumber:3
Organization:
      name:Springer Milan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Piramal Imaging GmbH
      address:
         name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
         type:PostalAddress
      name:Piramal Imaging GmbH
      address:
         name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ana M. Catafau
      affiliation:
            name:Piramal Imaging GmbH
            address:
               name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Santiago Bullich
      affiliation:
            name:Piramal Imaging GmbH
            address:
               name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany
      name:Clinical R&D Neurosciences, Piramal Imaging GmbH, Berlin, Germany

External Links {🔗}(343)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.04s.